Senseonics Launches the Eversense® Bridge Patient Access Program in the U.S.
March 22 2019 - 8:00AM
Business Wire
Patients Can Access Long-term Eversense CGM for only $99*
Under Program
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and commercialization
of a long-term, implantable continuous glucose monitoring (CGM)
system for people with diabetes, has announced the launch of the
Eversense Bridge Program. Under the program, patients can access
the Eversense CGM System, the only long-term CGM that lasts up to
90 days, for only $99* plus the cost of the sensor placement by the
healthcare provider.
“The Eversense Bridge Program is an important strategic
initiative with the goal of providing access to eligible patients
who have high out-of-pocket costs, are waiting for a favorable
coverage policy, or have been denied insurance coverage for
Eversense,” said Tim Goodnow, President and CEO of Senseonics.
“Insurance companies unfamiliar with the newest approved diabetes
technology may deny coverage for a wide range of insured patients
who have come forward demanding this technology. We developed this
program to reduce barriers for patients who seek access to this
technology right away. Every patient who qualifies for the program
will now have improved access to this innovative diabetes
management technology.”
The Eversense Bridge Program is a patient access program
designed to assist patients with confirming their insurance
benefits, obtaining pre-authorizations before the sensor placement
and working with their healthcare provider’s office to help
patients with the appeals of denied claims. From start to finish,
the Eversense Bridge Program has been created to help the
healthcare providers and patients have easier access to Eversense
CGM.
The Eversense CGM System is a unique alternative for continuous
monitoring of glucose. It consists of a fluorescence-based sensor,
a smart transmitter worn over the sensor to facilitate data
communication, and a mobile app for displaying glucose values,
trends and alerts. Unlike traditional CGMs, Eversense is the first
and only implantable CGM sensor in the United States and has the
longest duration of up to 90 days. It features a smart transmitter
that provides discreet, on-body vibratory alerts for high and low
glucose and can be removed, recharged and re-adhered without
discarding the sensor. The sensor is inserted subcutaneously in the
upper arm by a health care provider via a brief in-office
procedure.
"I commend Senseonics for addressing the critical issue
of access barriers to new medical technology. Diabetes
equipment and supplies are very expensive for patients, often even
with insurance coverage,” said Amy
Tenderich, DiabetesMine journalist/blogger and
diabetes advocate. “I am currently on my second Eversense
sensor. I chose to be reinserted based on the accuracy
and convenience this system provides. I am happy
that the Eversense Bridge Program will allow many more
patients to access this useful new tool.”
Patients who are interested in getting started on Eversense
through the Eversense Bridge Program can sign up at
eversensediabetes.com/patient-bridge. Physicians, nurse
practitioners or physician assistants interested in offering the
Eversense CGM System for their patients can contact Senseonics at
844-SENSE4U (844-736-7348).
Additionally, as previously disclosed in its Annual Report on
Form 10-K for the year ended December 31, 2018, which was filed
with the Securities and Exchange Commission (SEC) on March 15,
2019, Senseonics’ audited consolidated financial statements
contained an audit opinion from its independent registered public
accounting firm that included an explanatory paragraph relating to
Senseonics’ ability to continue as a going concern. This
announcement is made pursuant to NYSE-American Company Guide
Sections 401(h) and 610(b), which require public announcement of
the receipt of an audit opinion containing a going concern
qualification. This announcement does not represent any change or
amendment to Senseonics’ consolidated financial statements or to
its Annual Report on Form 10-K for the year ended December 31,
2018.
* For a limited time, patients who meet the program’s
eligibility requirements may receive financial assistance towards
acquiring the Eversense CGM System (after making an initial $99
payment). The Eversense Bridge Program does not apply to sensor
placement procedure fees from patients’ healthcare providers,
however, and patients must discuss coverage and payment for sensor
placement separately with their physician (or other health care
provider). The Eversense Bridge Program is not available for
patients insured through federal healthcare programs or residents
of certain states. To see full terms and conditions, please visit
www.eversensediabtes.com/patient-bridge.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 90 days. It is intended to
complement, not replace, fingerstick blood glucose monitoring. The
sensor insertion and removal is performed by a health care
provider. The Eversense CGM System is a prescription device;
patients should talk to their health care provider to learn more.
For important safety information,
see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a
small sensor inserted completely under the skin that communicates
with a smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Senseonics, including statements about the
Eversense Bridge Program, and the benefits, advantages and
convenience such program offers people with diabetes, and other
statements containing the words “believe,” “expect,” “intend,”
“may,” “projects,” “will,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: uncertainties
inherent in the commercial launch and commercial expansion of the
Eversense product, including without limitation patient adoption
and insurance coverage, and such other factors as are set forth in
the risk factors detailed in Senseonics’ Annual Report on Form 10-K
for the year ended December 31, 2018 and Senseonics’ other filings
with the SEC under the heading “Risk Factors.” In addition, the
forward-looking statements included in this press release represent
Senseonics’ views as of the date hereof. Senseonics anticipates
that subsequent events and developments will cause Senseonics’
views to change. However, while Senseonics may elect to update
these forward-looking statements at some point in the future,
Senseonics specifically disclaims any obligation to do so except as
required by law. These forward-looking statements should not be
relied upon as representing Senseonics’ views as of any date
subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190322005026/en/
Senseonics Investor Contact:Lynn Lewis or Philip
TaylorInvestor Relations415-937-5406investors@senseonics.com
Senseonics Media Contact:SignalWest Public RelationsJeff
Christensen, 831-566-0275jeff@signalwestpr.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Apr 2023 to Apr 2024